1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. HEREDITARY TESTING MARKET BY DISEASE TYPE
5.1. Introduction
5.2. Hereditary Cancer Testing
5.3. Hereditary Non-Cancer Testing
6. HEREDITARY TESTING MARKET BY TECHNOLOGY
6.1. Introduction
6.2. Cytogenetic
6.3. Biochemical
6.4. Molecular Testing
7. HEREDITARY TESTING MARKET BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Others
8. HEREDITARY TESTING MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. MedGenome
10.2. Myriad Genome
10.3. Mapmygenome
10.4. Invitae
10.5. Ambry Genetics
10.6. 23andMe
10.7. ARUP Laboratories
10.8. GeneDx
10.9. Criver
10.10. Medline Plus
10.11. Mayo Clinic
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES